Reprogramming the Cancer Immunity Cycle
We are advancing a robust pipeline of therapeutic agents designed to modulate the Cancer Immunity Cycle through multiple mechanisms and targets, including cancer cells, components of tumor microenvironments (TMEs) and various types of immune cells.